Critical Analysis: Medpace (NASDAQ:MEDP) and Amarantus Bioscience (OTCMKTS:AMBS)

Medpace (NASDAQ:MEDP) and Amarantus Bioscience (OTCMKTS:AMBS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Medpace and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	18.36%	91.88%	23.65%
Amarantus Bioscience	N/A	N/A	N/A

Earnings and Valuation

This table compares Medpace and Amarantus Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.11 billion	7.92	$404.39 million	$14.30	41.47
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

Medpace has higher revenue and earnings than Amarantus Bioscience.

Analyst Recommendations

This is a summary of recent ratings and target prices for Medpace and Amarantus Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	3	10	2	0	1.93
Amarantus Bioscience	0	0	0	0	0.00

Medpace currently has a consensus target price of $491.27, indicating a potential downside of 17.16%. Given Amarantus Bioscience’s higher probable upside, analysts clearly believe Amarantus Bioscience is more favorable than Medpace.

Institutional and Insider Ownership

78.0% of Medpace shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 10.3% of Amarantus Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Medpace has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

Summary

Medpace beats Amarantus Bioscience on 8 of the 10 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.